Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Fatima H Karzai, M.D.
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tulane University
New Orleans, Louisiana, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
- Brigham and Women S Hospital
Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Dec 2019
- Primary completion
- 19 Nov 2027
- Completion
- 19 Nov 2027
- Last update posted
- 8 Sept 2026
- Registered enrollment
- 175
- Registry id
- NCT03976843
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.